Please assess the completion status of the following clinical trial:

Trial Title: This is a Study to Determine the Antidepressant Effects of AZD6765

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a diagnosis of Major Depressive Disorder, currently depressed without psychotic features~* Females must be of non-childbearing potential.~Exclusion Criteria:~* Treatment with Clozapine or ECT within 3 months prior to study~* Current or past history of psychotic features or a diagnosis of schizophrenia or any other psychotic disorder as defined in the DSM-IV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- AZD6765 (150 mg) / Placebo (Type: EXPERIMENTAL): Patients randomized to receive a single intravenous (iv) infusion of AZD6765 (150 mg) over 60 minutes during the first period, followed by a 7-day drug-free period, followed by a single iv infusion of placebo (saline solution) over 60 minutes during the second period.
- Placebo / AZD6765 (150 mg) (Type: PLACEBO_COMPARATOR): Patients randomized to receive a single intravenous (iv) infusion of placebo (saline solution) over 60 minutes during the first period, followed by a 7-day drug-free period, followed by a single iv infusion of AZD6765 (150 mg) over 60 minutes during the second period.

Based on this trial design, predict the completion outcome and termination type (if applicable).